Related Experiment Video
Updated: May 1, 2026
04:36
Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors
Published on: October 17, 2025
1.1K
FLT3 inhibitors in AML: are we there yet?
Akshay Sudhindra1, Catherine Choy Smith
1University of California, San Francisco, 505 Parnassus Ave, Box 1270, San Francisco, CA, 94143, USA, Akshay.Sudhindra@ucsf.edu.
Current Hematologic Malignancy Reports
|April 1, 2014
Summary
FMS-like tyrosine kinase 3 (FLT3) inhibitors show promise for acute myeloid leukemia (AML) patients with FLT3 mutations. Newer agents improve responses but face challenges with resistance development.
Area of Science:
- Hematology
- Oncology
- Pharmacology
Background:
- FMS-like tyrosine kinase 3 (FLT3) mutations are common in acute myeloid leukemia (AML), affecting approximately 30% of patients.
- Activating mutations include internal tandem duplications (FLT3-ITD) and tyrosine kinase domain point mutations (FLT3 TKD).
Purpose of the Study:
- To review FLT3 inhibitors evaluated in clinical trials for AML.
- To discuss the challenges associated with using these targeted agents in AML treatment.
Main Methods:
- Review of clinical trial data for FLT3 inhibitors in AML.
- Analysis of inhibitor selectivity, potency, pharmacokinetics, and resistance mechanisms.
Main Results:
- Early FLT3 inhibitors had limited clinical activity due to poor selectivity, potency, and pharmacokinetics.
- Newer agents like quizartinib demonstrate improved potency and selectivity, leading to higher bone marrow response rates.
- Response duration remains limited by the emergence of secondary resistance.
Conclusions:
- FLT3 inhibitors represent a significant therapeutic advance for AML patients with FLT3 mutations.
- Overcoming resistance mechanisms and optimizing treatment strategies are crucial for improving long-term outcomes.
